Dr. Krakow is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
825 Eastlake Ave E
Seattle, WA 98109Phone+1 206-520-5700
Education & Training
Universite de MontrealFellowship, 2010 - 2014- McMaster UniversityFellowship, 2006 - 2008
Duke University HospitalResidency, Internal Medicine, 2003 - 2006
McGill University Faculty of MedicineClass of 2003
Certifications & Licensure
WA State Medical License 2009 - 2026
Clinical Trials
- Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Start of enrollment: 2020 Jan 02
- IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation Start of enrollment: 2021 Mar 08
Publications & Presentations
PubMed
- 39 citationsNaive T-Cell Depletion to Prevent Chronic Graft-Versus-Host Disease.Marie Bleakley, Alison Sehgal, Stuart Seropian, Melinda A Biernacki, Elizabeth F Krakow
Journal of Clinical Oncology. 2022-04-10 - 24 citationsRates and Risk Factors for Post-Traumatic Stress Disorder Symptomatology among Adult Hematopoietic Cell Transplant Recipients and Their Informal Caregivers.Jessica Liang, Stephanie J. Lee, Barry E. Storer, Bronwen E. Shaw, Eric J. Chow
Biology of Blood and Marrow Transplantation. 2019-01-01 - 5 citationsOutcomes after hematopoietic cell transplantation among non-English- compared to English-speaking recipients.Ahona Mukherjee, Ted Gooley, Marco Mielcarek, Brenda M Sandmaier, Kris Doney
Bone Marrow Transplantation. 2022-03-01
Abstracts/Posters
- BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)Elizabeth Krakow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II StudyElizabeth Krakow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- BMT CTN 1803: Haploidentical Natural Killer Cells (CSTD002) to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM)Elizabeth Krakow, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
ElevateBio’s HighPassBio Presents on Novel T Cell Receptor Cell Therapy for Leukemia Relapse at 62nd Annual ASH MeetingDecember 6th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
